Navigation Links
Phase 3 Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Therapi
Date:1/17/2012

as compared to placebo.[i]

Per the recommendation from an independent Data Monitoring Committee, the CORRECT study was unblinded in late 2011 following a pre-planned interim analysis that determined that the regorafenib arm showed significant improvement in overall survival; patients on the placebo arm were unblinded and offered treatment with regorafenib.

Bayer plans to submit regorafenib for marketing authorization in mCRC in 2012.

In 2011, Bayer and Onyx entered into an agreement under which Onyx will receive a royalty on any future global net sales of regorafenib in oncology.

About the CORRECT Study

The CORRECT study was an international, multicenter, randomized, double-blind, placebo-controlled Phase 3 study that enrolled 760 patients with mCRC whose disease had progressed during or within 3 months following last administration of approved standard therapies, which must have included fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab and cetuximab or panitumumab.[i]

Patients who had withdrawn from standard treatment due to unacceptable toxicity warranting discontinuation of treatment and precluding retreatment with the same agent prior to progression of disease were also allowed into the study.

Patients were randomized to receive either regorafenib plus best supportive care (BSC) or placebo plus BSC. Treatment cycles consisted of 160 mg of regorafenib (or matching placebo) once daily for three weeks on / one week off plus BSC.[i]

The study was conducted in North America, Europe, China, Japan and Australia.

About Colorectal Cancer

Colorectal cancer (CRC) is a disease in which malignant (cancer) cells form in the tissues of the colon or rectum. The majority of cancers occurring in the colon and rectum are adenocarcinomas, which account for more than 90 percent of all large bowel tumors.[ii]

CRC is the third most commonly diagnosed cancer and the third leading cau
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339
2. Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
3. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
4. Suneva Medical to Pursue Expanded Indications for Artefill® With Launch of Phase III Acne Scar Study
5. Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI): Phase III Data on Bayers Investigational Compound Regorafenib (BAY 73-4506) in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Or
6. Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program
7. Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer Patients
8. Pearl Therapeutics Announces Successful Completion of Phase 2b Safety and Efficacy Studies of COPD Combination, PT003
9. DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial)
10. Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
11. ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 24 novembre 2014  Surgical Theater LLC ... sarà esposta durante l,apertura in data 24 ... ossia la Fondazione IRCCS Istituto Neurologico Nazionale ... (SRP) (strumento di pianificazione chirurgica) e Surgical ... chirurgica avanzata) saranno presentati in occasione dell,evento ...
(Date:11/24/2014)... Pa. , Nov. 24, 2014  Inovio Pharmaceuticals, Inc. ... J. Joseph Kim , President and CEO of Inovio Pharmaceuticals, ... management team to ring the Nasdaq Opening Bell tomorrow, Tuesday ... Inovio,s September 15 th listing on the Nasdaq Global ... ceremony, Dr. Kim said, "We are honored to ring the ...
(Date:11/23/2014)... -- Aurobindo Pharma USA is voluntarily ... 100-count bottles to the consumer level. The product lot ... Empty capsules could result in missed dose(s) of ... from no effect, short term reduction in efficacy, short ... that could be life-threatening. Aurobindo Pharma USA ...
Breaking Medicine Technology:La tecnologia di Surgical Theater in mostra in Italia all'apertura del centro Besta NeuroSim di Milano 2La tecnologia di Surgical Theater in mostra in Italia all'apertura del centro Besta NeuroSim di Milano 3La tecnologia di Surgical Theater in mostra in Italia all'apertura del centro Besta NeuroSim di Milano 4Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market 2Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market 3Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Northstar Label Gabapentin Capsules, USP 300 mg Due to Complaints of Empty Capsules 2
... board of directors of Eli Lilly and Company (NYSE: ... quarter of 2012 of $0.49 a share on outstanding common ... 2012 to shareholders of record at the close of business ... corporation, is developing a growing portfolio of pharmaceutical products by ...
... CHICAGO, April 16, 2012  Swedish Covenant Hospital today announced ... case using Curve™ Image Guided Surgery by Brainlab, the ... "Having the option to use image guidance ... increases the flexibility and visualization in these types of ...
Cached Medicine Technology:Curve Image Guided Surgery Provides Swedish Covenant Hospital With a State-of-the-Art Command and Control Center for Information-Guided Surgery 2Curve Image Guided Surgery Provides Swedish Covenant Hospital With a State-of-the-Art Command and Control Center for Information-Guided Surgery 3
(Date:11/24/2014)... Residents of retirement communities in Ohio and ... GOT TALENT, an annual online talent competition and showcase ... classic crooners, to seniors partying on a “night on ... living young. , “SENIORS GOT TALENT, while still having ... has always been about highlighting the vibrancy of being ...
(Date:11/24/2014)... 24, 2014 Olaparib functions as a ... and is one of the first PARP inhibitors. Sufferers ... some types of melanoma, and are often immune to ... gives their malignancies a exclusive weaknesses, as the tissues ... their DNA and allow them to proceed splitting. This ...
(Date:11/24/2014)... The Holiday Inn Westbury - Long ... Children's Association to donate various items consisting of ... other such items.The Association's program is aimed toward helping ... in nursing homes, assisted living facilities and nursing homes. ... being of seniors throughout the Long Island area. The ...
(Date:11/24/2014)... Mental health issues affect tens of ... families, ruin careers, and generally destroy lives. , ... suffer,” says Hardy Nutritionals® founder David ... specialized nutritional treatments can reverse these disorders naturally.” ... Matter”, the premiere episode of O2 Media’s new ...
(Date:11/24/2014)... November 24, 2014 SafeHandles™ announced that ... Innovations with Ed Begley Jr, airing via Discovery Channel. ... to provide a passive, non-invasive, replaceable, and affordable germ ... incorporates custom-fit shrinkable sleeves and adhesives to promote hand ... “At the core of SafeHandles is the desire to ...
Breaking Medicine News(10 mins):Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 2Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 4Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 2Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 3Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2
... , THURSDAY, April 7 (HealthDay News) -- A new method ... percent of hospital mistakes are overlooked. The actual error ... recent focus on reducing error rates and improving patient safety, ... errors, the more you find," said lead researcher Dr. David ...
... New Rochelle, NY, April 7, 2011A growing body of ... contribute to the development and poor control of type ... article in the inaugural issue of Journal of ... Science, a quarterly peer-reviewed journal from Mary Ann Liebert, ...
... (HealthDay News) -- Young women whose intimate partners try ... and sexual domestic violence, a new study finds. ... 24 who were patients at a reproductive health center. ... Of those women, 38 percent said they experienced ...
... THURSDAY, April 7 (HealthDay News) -- After hooking up a ... computer to "read" the thoughts of disabled patients, thereby enabling ... researchers are hoping the breakthrough will one day lead to ... around them. "We have been fundamentally interested in creating ...
... 7, 2011 Cheryl A. Kerfeld, a structural biologist ... Joint Genome Institute,s Education and Structural Genomics Programs, has ... Award for Exemplary Contributions to Education. Kerfeld will present ... p.m. on April 10 at the Experimental Biology 2011 ...
... A new study from Mayo Clinic ( http://www.mayoclinic.com/ ), ... to date, demonstrates that progressive damage to kidney transplants ... reported. The study, involving 797 patients transplanted ... five years, shows that 87 percent of patients have ...
Cached Medicine News:Health News:Report: Hospital Errors May Be Far More Common Than Suspected 2Health News:Report: Hospital Errors May Be Far More Common Than Suspected 3Health News:Caffeine and diabetes -- helpful or harmful? 2Health News:For Young Women, 'Controlling' Partner Often Abusive, Too 2Health News:Scientists Use Computer to 'Read' Human Thoughts 2Health News:Scientists Use Computer to 'Read' Human Thoughts 3Health News:US Department of Energy programs leader wins education award 2Health News:Long-term study shows that kidney transplants are faring better than previously reported 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: